Belgian biotech Galapagos (NASDAQ:GLPG) announced a major restructuring drive on Wednesday, with plans to amend its 10-year ...

This was the stock's fifth consecutive day of losses.

This was the stock's fourth consecutive day of losses.

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its current workforce.

According to Benzinga Pro, Gilead Sciences's peer group average for short interest as a percentage of float is 5.13%, which ...

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...